Analyzing Dyne Therapeutics (NASDAQ:DYN) & MediWound (NASDAQ:MDWD)

Dyne Therapeutics (NASDAQ:DYN) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares Dyne Therapeutics and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.46%	-50.94%
MediWound	-140.80%	-65.79%	-30.16%

Risk and Volatility

Dyne Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Valuation & Earnings

This table compares Dyne Therapeutics and MediWound”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.54)	-5.12
MediWound	$16.96 million	12.17	-$23.88 million	($2.10)	-7.67

MediWound has higher revenue and earnings than Dyne Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Dyne Therapeutics and MediWound, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	2	11	3	2.94
MediWound	1	1	3	0	2.40

Dyne Therapeutics presently has a consensus target price of $35.14, indicating a potential upside of 93.84%. MediWound has a consensus target price of $31.67, indicating a potential upside of 96.57%. Given MediWound’s higher possible upside, analysts clearly believe MediWound is more favorable than Dyne Therapeutics.

Summary

Dyne Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.